Taspoglutide 产品活性：Taspoglutide是长效 GLP-1 受体激动剂, EC50值为0.06 nM，可用于 2 型糖尿病的相关研究。 产品来源： https://www.medchemexpress.cn/Taspoglutide.html 研究领域：GPCR/G Protein 作用靶点：GCGR In Vitro: Taspoglutide (R1583/BIM51077) is a long acting 10% formulation of (Aib8-35) human GLP-1 (7-36 amides) with 93% homology with the native polypeptide. It activates the GLP-1 receptor. Taspoglutide has comparable affinity (affinity constant 1.1±0.2 nM) to the natural ligand (affinity constant 1.5±0.3 nM) for the hGLP-1 receptor and exhibits comparable potency in stimulating cAMP production. In Vivo: Taspoglutide has been shown to enhance the rate of glucose-induced insulin secretion from isolated, cultured rat islets and the perfused ZDF rat pancreas. Taspoglutide in Sprague-Dawley rats and diabetic db/db mice have shown a dose-related enhancement of glucose-dependent insulin release, which lower blood glucose in the db/db mouse model of type 2 diabetes. Acute treatment with taspoglutide reduces glucose excursion and increased insulin response during oGTT. In chronically treated rats, glucose excursion and levels of GIP, PYY and triglycerides during oGTT on day 21 are significantly reduced. Hepatic triglyceride levels are significantly reduced in livers from taspoglutide-treated. Taspoglutide does not reduce plaque area or lipid content in the aortic arch or abdominal aorta, and no significant change in aortic macrophage accumulation is detected after taspoglutide or metformin mice. 相关产品：Drug Repurposing Compound Library Plus | Clinical Compound Library Plus | Bioactive Compound Library Plus | Peptide Library | Semaglutide | Exendin-4 | Liraglutide | Glucagon (1-29), bovine, human | Exendin(9-39) amide | Retatrutide | Orforglipron | GLP-1(7-37) | GLP-1(7-36), amide acetate | MK 0893 | Adomeglivant | BETP | Cotadutide acetate | GLP-1R Antagonist 1 | Danuglipron | GLP-1(9-36)amide | GLP-2(1-33)(human) | Oxyntomodulin (bovine, porcine) | Lixisenatide | Beinaglutide | Lotiglipron | Survodutide | NNC-0640 | Mazdutide | GLP-1R agonist 2 | LGD-6972 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。